

Sajad J Khazal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4182309/publications.pdf>

Version: 2024-02-01

56
papers

637
citations

759233

12
h-index

642732

23
g-index

57
all docs

57
docs citations

57
times ranked

901
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	3.5	9
2	Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 116-128.	5.6	17
3	Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 1908-1919.	1.4	34
4	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancers</i> , 2022, 14, 150.	3.7	30
5	Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. <i>Cancers</i> , 2022, 14, 2912.	3.7	4
6	Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28839.	1.5	3
7	Improved detection of sinusoidal obstructive syndrome using pediatric AYA diagnostic criteria and severity grading. <i>Bone Marrow Transplantation</i> , 2021, 56, 175-184.	2.4	13
8	Care of the Critically Ill Pediatric Hematopoietic Cell Transplant Patient. , 2021, , 1207-1241.		0
9	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	2.8	7
10	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
11	The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.6	2
12	Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?. <i>Frontiers in Oncology</i> , 2021, 11, 634445.	2.8	23
13	Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. <i>Leukemia and Lymphoma</i> , 2021, 62, 2831-2844.	1.3	3
14	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. <i>Blood Advances</i> , 2021, 5, 1-11.	5.2	46
15	Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita. <i>Pediatric Transplantation</i> , 2021, , e14157.	1.0	1
16	Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. <i>Cancers</i> , 2021, 13, 5814.	3.7	3
17	DNMT3A Mutations Should be Considered in the Risk Stratification for Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1308-1308.	1.4	0
18	Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. <i>Blood</i> , 2021, 138, 1247-1247.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	4.6	56
20	Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. <i>EClinicalMedicine</i> , 2020, 26, 100514.	7.1	5
21	Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD19 chimeric antigen receptor T cell therapy. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1678-1681.	0.5	7
22	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 713-719.	0.4	9
23	Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. <i>Frontiers in Oncology</i> , 2020, 10, 1227.	2.8	1
24	Primary mediastinal large B cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. <i>British Journal of Haematology</i> , 2020, 190, e114-e117.	2.5	5
25	Epstein Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein barr virus mucocutaneous ulcer. <i>British Journal of Haematology</i> , 2020, 189, e33-e36.	2.5	3
26	Incidence and Outcomes of Patients with Thrombotic Microangiopathy after Transplant: Results of Prospective Screening through a Multi-Institutional Collaborative. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S92.	2.0	3
27	Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1054.	4.1	61
28	Transfusion Reactions in Pediatric and Young Adult Hematopoietic Stem Cell Transplant and Oncology Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S149.	2.0	0
29	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2020, , 2035-2047.		0
30	IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii361-iii361.	1.2	0
31	Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S316.	2.0	0
32	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
33	IMMU-52. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii116-ii116.	1.2	0
34	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.	27.6	178
35	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2019, , 1-13.		1
36	Bone Marrow Failure. , 2019, , 95-107.		0

#	ARTICLE	IF	CITATIONS
37	Abstract 1345: Automated capture and analysis of circulating tumor cells across different types of tumors in pediatric cancer patients. , 2019, , .		0
38	Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson. Blood, 2019, 134, 4495-4495.	1.4	0
39	Abstract 1345: Automated capture and analysis of circulating tumor cells across different types of tumors in pediatric cancer patients. , 2019, , .		0
40	Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of late-onset primary isolated central nervous system hemophagocytic lymphohistiocytosis. Pediatric Transplantation, 2018, 22, e13101.	1.0	11
41	High Dose Chemotherapy Followed by Autologous Stem Cell Rescue for High Risk Soft Tissue Sarcoma: Retrospective Review. Biology of Blood and Marrow Transplantation, 2018, 24, S138.	2.0	0
42	The PI3KÎ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers, 2017, 9, 121.	3.7	14
43	5-Azacitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-Dose Chemotherapy. Pediatric Blood and Cancer, 2016, 63, 1111-1112.	1.5	3
44	Am80â€•<sc>GCSF</sc> synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropeniaâ€•associated infection andÂ•mortality. EMBO Molecular Medicine, 2016, 8, 1340-1359.	6.9	10
45	Reduced Intensity Conditioning Followed By Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Cure of a 15 Year Old Male with Primary Isolated CNS Late Onset Familial Hemophagocytic Lymphohistiocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, S347-S348.	2.0	0
46	Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency. Blood, 2016, 128, 735-737.	1.4	3
47	5-Azacitidine Monotherapy Followed By Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient with Acute Undifferentiated Leukemia Refractory to High Dose Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, S206-S207.	2.0	0
48	Stable Mixed Donor Chimerism after Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen in a 4 Year Old Boy with Congenital Non Spherocytic Hemolytic Anemia Secondary to Hexokinase Deficiency. Biology of Blood and Marrow Transplantation, 2016, 22, S331.	2.0	0
49	Unrelated Donor Hematopoietic Stem Cell Transplantation for Treatment of Non-Malignant Genetic Diseases Using a Myeloablative Reduced Toxicity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, S239.	2.0	0
50	Unrelated donor hematopoietic stem cell transplantation for the treatment of nonâ€•malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. American Journal of Hematology, 2015, 90, 1021-1026.	4.1	9
51	The PI3Kdelta Inhibitor, CAL-101, Inhibits Migration of Primary Pre-B ALL to SDF1alpha: Treatment Implications for Overcoming Cell-Adhesion-Mediated Drug Resistance. Blood, 2015, 126, 2526-2526.	1.4	0
52	Overcoming Psychosocial and Developmental Barriers to Blood and Marrow Transplantation (BMT) in an Adolescent/Young Adult (AYA) Transgender Patient with Chronic Myelogenous Leukemia. Pediatric Hematology and Oncology, 2014, 31, 765-767.	0.8	4
53	PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL. Blood, 2014, 124, 3715-3715.	1.4	0
54	VLA4 Blockade In Acute Myeloid Leukemia. Blood, 2013, 122, 3944-3944.	1.4	16

#	ARTICLE	IF	CITATIONS
55	Assessment of knowledge of vincristine toxicities in outpatient pediatric hematology/oncology nurses: An educational intervention.. Journal of Clinical Oncology, 2013, 31, 231-231.	1.6	8
56	Molecular Pathogenesis of Acute Lymphoblastic Leukemia. , 0, , 67-67.		0